Recent 8-K filings for HNGE

• August 4, 2026, 4:08 PM ET earnings materiality 0.85 positive item 2.02item 7.01item 8.01item 9.01

  Hinge Health Q2 revenue $212.8M (+53% YoY), raises FY guidance, acquires Cylinder Health for $105M

  Revenue $212.8M (+53% YoY); GAAP EPS $0.52, non-GAAP EPS $0.59.

• June 9, 2026, 4:06 PM ET earnings materiality 0.75 positive item 7.01item 9.01

  Hinge Health raises FY 2026 revenue guidance to $818-824M, up $20M at midpoint

  FY 2026 revenue guided $818-824M, up from prior range; represents 40% YoY growth at midpoint.

• June 4, 2026, 4:19 PM ET other material materiality 0.10 neutral item 5.07 ◈ Shareholder Votes ×2

  Hinge Health stockholders elect Teddie Wardi and Tyler Sloat as Class I directors, ratify Deloitte as auditor

  Teddie Wardi received ~276.9M votes for, ~14.9M withheld; Tyler Sloat received ~291.3M for, ~0.5M withheld.

• May 5, 2026, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 7.01item 9.01 ◈ Earnings Releases

  Hinge Health Q1 revenue $182M (+47% YoY), EPS $0.41; raises FY guidance to $801M

  Revenue of $182.3M, +47% YoY; GAAP diluted EPS $0.41, non-GAAP $0.45.

• March 17, 2026, 7:59 PM ET leadership materiality 0.35 neutral item 5.02

  Hinge Health appoints Tyler Sloat to Board of Directors, effective March 16, 2026

  Tyler Sloat appointed as Class I director; term expires at 2026 annual meeting.

• February 10, 2026, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 7.01item 9.01

  Hinge Health Q4 revenue $170.7M (+46% YoY); guides FY26 rev $732-742M

  Q4 revenue $170.7M (+46% YoY); GAAP diluted EPS $0.37, non-GAAP $0.49.

• November 12, 2025, 6:59 PM ET other material materiality 0.65 positive item 7.01item 8.01item 9.01

  Hinge Health authorizes $250M share repurchase; Q3 free cash flow $118M

  Board approved up to $250M repurchase of Class A common stock on Nov 10, 2025.

• November 4, 2025, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 7.01item 9.01

  Hinge Health Q3 revenue $154.2M (+53% YoY); raises FY 2025 guidance

  Revenue $154.2M vs $100.6M in Q3 2024, +53% YoY; GAAP gross margin 82% vs 79%.

• August 13, 2025, 7:59 PM ET other material materiality 0.65 neutral item 8.01

  Hinge Health lock-up early release triggered; ~1.66M shares unlocked Aug 19

  Early release condition satisfied on Aug 6: stock price >120% of IPO price for 5+ days in 10-day window after Q1 earnings (Aug 5).

• August 5, 2025, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 7.01item 9.01

  Hinge Health Q2 revenue $139.1M (+55% YoY); non-GAAP operating income $26.1M; guides FY revenue $548-552M

  Revenue grew 55% YoY to $139.1M; GAAP gross margin 70%, non-GAAP gross margin 83%.

• May 23, 2025, 7:59 PM ET other material materiality 0.85 positive item 5.03item 8.01item 9.01 ◈ Governance Changes ×2

  Hinge Health completes IPO of 15.7M shares at $32.00, raising $272.7M in gross proceeds

  IPO closed May 23, 2025; 15,715,900 shares of Class A common stock sold at $32.00 per share.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.80 · Most common event earnings

8 positive 0 negative 3 neutral

source · HNGE on sec.gov